润都股份：关于单硝酸异山梨酯片获得药品注册证书的公告

Core Viewpoint - Rundu Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for Isosorbide Mononitrate Tablets, which are indicated for the long-term treatment of coronary heart disease, prevention of angina pectoris, treatment of persistent angina after myocardial infarction, and treatment of chronic congestive heart failure in combination with digoxin and/or diuretics [2]. Company Summary - The drug Isosorbide Mononitrate Tablets is specifically designed for the long-term management of coronary heart disease and related conditions [2]. - The approval of this drug may enhance the company's product portfolio and market presence in the cardiovascular treatment segment [2].